2025
Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial
Grilo C, Ivezaj V, Yurkow S, Tek C, Gueorguieva R. Cognitive‐Behavioral Therapy and Lisdexamfetamine, Alone and Combined, for Binge‐Eating Disorder: Secondary Outcomes of a Randomized Controlled Trial. International Journal Of Eating Disorders 2025 PMID: 40631364, PMCID: PMC12268943, DOI: 10.1002/eat.24502.Peer-Reviewed Original ResearchCognitive-behavioral therapyOvervaluation of shape/weightDifferential treatment responseRandomized Controlled TrialsBinge-eating disorderCognitive-behavioralDelay discountingBinge eatingPosttreatment assessmentLisdexamfetamineTreatment responseSecondary outcomesControlled TrialsTreatment effectsIndividualized treatmentBinge-eatingShape/weightBingePrimary outcomeEatingSignificant improvementDisordersMetabolic variablesPosttreatmentSignificant effectSecondary Analysis to Advance Characterization of On-body Electrocardiographic Sensors in a Clinical Cocaine Self-administration Paradigm
Angarita G, Mayerson T, Pittman B, Natarajan A, Parate A, Marlin B, Gueorguieva R, Potenza M, Ganesan D, Malison R. Secondary Analysis to Advance Characterization of On-body Electrocardiographic Sensors in a Clinical Cocaine Self-administration Paradigm. Journal Of Addiction Medicine 2025 DOI: 10.1097/adm.0000000000001479.Peer-Reviewed Original ResearchCocaine useCocaine self-administration paradigmCocaine Self-AdministrationSelf-administration paradigmTobacco useHeart rateMethylphenidate administrationSelf-AdministrationCocaineDiscriminatory powerAerobic exerciseReceiver Operating CharacteristicMethylphenidateSecondary analysisPrimary outcomeElectrocardiogram tracingsElectrocardiogramExerciseR waveHeartTobaccoOperating characteristicsSwitching from menthol to non-menthol cigarettes does not impact acute responses to intravenous nicotine
Wolkowicz N, Parida S, Gueorguieva R, Sofuoglu M. Switching from menthol to non-menthol cigarettes does not impact acute responses to intravenous nicotine. Pharmacology Biochemistry And Behavior 2025, 249: 173985. PMID: 40010441, PMCID: PMC11932434, DOI: 10.1016/j.pbb.2025.173985.Peer-Reviewed Original ResearchConceptsContinuous Performance TestResponse to nicotineNicotine infusionNon-menthol cigarettesAcute responses to nicotineExperimental sessionsIntravenous nicotine infusionsNicotine metabolite ratioSmoking conditionsDaily cigarette smokingTobacco withdrawalWithdrawal severitySmoking urgesNicotine administrationCigarette consumptionIntravenous nicotineSmoking menthol cigarettesDrug effectsNicotineReduce cigarette consumptionHeart rate responseMetabolite ratiosBlood levelsPrimary outcomeInfusion period
2022
Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic
Bondar J, Morrow C, Gueorguieva R, Brown M, Hawrilenko M, Krystal JH, Corlett PR, Chekroud AM. Clinical and Financial Outcomes Associated With a Workplace Mental Health Program Before and During the COVID-19 Pandemic. JAMA Network Open 2022, 5: e2216349. PMID: 35679044, PMCID: PMC9185188, DOI: 10.1001/jamanetworkopen.2022.16349.Peer-Reviewed Original ResearchConceptsMental health programsHealth programsCohort studyLarge clinical effect sizesPatient Health Questionnaire-9Common mental health conditionsSheehan Disability ScaleClinical effect sizeMental health conditionsMental health symptomsCost of treatmentGeneralized anxiety disorderMental health difficultiesMental health benefitsWorkplace wellness programsCare navigationClinical improvementPrimary outcomeClinical benefitQuestionnaire-9Disability ScaleMedication managementLeast moderate anxietyMixed-effects regressionPerson psychotherapy
2021
Smartband-Based Automatic Smoking Detection and Real-time Mindfulness Intervention: Protocol for a Feasibility Trial
Horvath M, Grutman A, O'Malley SS, Gueorguieva R, Khan N, Brewer JA, Garrison KA. Smartband-Based Automatic Smoking Detection and Real-time Mindfulness Intervention: Protocol for a Feasibility Trial. JMIR Research Protocols 2021, 10: e32521. PMID: 34783663, PMCID: PMC8663689, DOI: 10.2196/32521.Peer-Reviewed Original ResearchBrief mindfulness interventionMindfulness interventionSmoking eventsINTERNATIONAL REGISTERED REPORT IDENTIFIERBrief mindfulness exerciseQuit dateSmartphone appMindfulness exercisesTreatment fidelitySmoking cessationDaily smokersUnique potential advantagesAvailable smartphone appsThree-step interventionCessation interventionsEnd of treatmentFeasibility measuresParticipantsFeasibility trialInterventionSecondary outcomesPrimary outcomeSmoking detectionPreventable deathsPilot trial
2020
Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study
Grilo CM, Lydecker JA, Morgan PT, Gueorguieva R. Naltrexone + Bupropion Combination for the Treatment of Binge-eating Disorder with Obesity: A Randomized, Controlled Pilot Study. Clinical Therapeutics 2020, 43: 112-122.e1. PMID: 33218742, PMCID: PMC7902424, DOI: 10.1016/j.clinthera.2020.10.010.Peer-Reviewed Original ResearchConceptsBinge-eating disorderEating-disorder psychopathologyPilot RCTTreatment of BEDOutcome time pointDouble-blind treatmentPercentage of patientsControlled Pilot StudyDiscontinuation of medicationTreatment of bingeEvidence-based treatmentsBinge-eating frequencyBupropion combinationAdult patientsAdverse eventsComorbid obesitySecondary outcomesPrimary outcomeAcute effectsFunctional impairmentPlaceboLong-term effectsPatientsMost outcomesObesity
2017
Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer
Bold KW, Toll BA, Cartmel B, Ford BB, Rojewski AM, Gueorguieva R, O'Malley SS, Fucito LM. Personalized Intervention Program: Tobacco Treatment for Patients at Risk for Lung Cancer. The Journal Of Smoking Cessation 2017, 13: 244-247. PMID: 32431757, PMCID: PMC7236885, DOI: 10.1017/jsc.2017.24.Peer-Reviewed Original ResearchLung cancerTobacco treatmentBiomarker feedbackCessation/reductionStandard careExpired carbon monoxideLung cancer screeningPoint prevalence abstinenceCurrent smokersLung functionPrimary outcomeCessation ratesCessation therapyCancer screeningQuit ratesSkin carotenoidsPlasma bilirubinGain-framed messagesNovel biomarkersPatientsNovel interventionsCancerPast weekSequential interventionsGain-framed messagingMecamylamine treatment for alcohol dependence: a randomized controlled trial
Petrakis IL, Ralevski E, Gueorguieva R, O'Malley SS, Arias A, Sevarino KA, Jane JS, O'Brien E, Krystal JH. Mecamylamine treatment for alcohol dependence: a randomized controlled trial. Addiction 2017, 113: 6-14. PMID: 28710873, PMCID: PMC5725262, DOI: 10.1111/add.13943.Peer-Reviewed Original ResearchConceptsHeavy drinking daysDrinking daysAlcohol use disorderUse disordersAlcohol consumptionAlcohol dependenceDouble-blind clinical trialNicotinic acetylcholine receptor antagonistWeeks of treatmentAcetylcholine receptor antagonistCurrent alcohol dependenceSignificant differencesTreatment-seeking smokersMecamylamine treatmentPlacebo groupMonth 3Primary outcomeSmoking statusNicotine withdrawalReceptor antagonistNovel pharmacotherapiesClinical trialsManagement therapyMecamylamineTreatment groups
2016
RANDOMIZED TRIAL OF D‐CYCLOSERINE ENHANCEMENT OF COGNITIVE‐BEHAVIORAL THERAPY FOR PANIC DISORDER
Otto MW, Pollack MH, Dowd SM, Hofmann SG, Pearlson G, Szuhany KL, Gueorguieva R, Krystal JH, Simon NM, Tolin DF. RANDOMIZED TRIAL OF D‐CYCLOSERINE ENHANCEMENT OF COGNITIVE‐BEHAVIORAL THERAPY FOR PANIC DISORDER. Depression And Anxiety 2016, 33: 737-745. PMID: 27315514, PMCID: PMC5958622, DOI: 10.1002/da.22531.Peer-Reviewed Original ResearchConceptsCognitive behavioral therapyBenzodiazepine usePanic disorderDCS augmentationMulticenter trialD-cycloserineRecent multicenter trialPanic Disorder Severity ScaleExposure-based cognitive-behavioral therapySessions of treatmentStudy pillsPrimary outcomeRandomized trialsBaseline severityPrimary diagnosisAugmentation effectTreatment responseTreatment endpointBooster sessionsSeverity ScaleRole of severityBehavioral therapyDCS efficacyBeneficial effectsPilot study
2015
Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety.
O'Malley SS, Corbin WR, Leeman RF, DeMartini KS, Fucito LM, Ikomi J, Romano DM, Wu R, Toll BA, Sher KJ, Gueorguieva R, Kranzler HR. Reduction of alcohol drinking in young adults by naltrexone: a double-blind, placebo-controlled, randomized clinical trial of efficacy and safety. The Journal Of Clinical Psychiatry 2015, 76: e207-13. PMID: 25742208, PMCID: PMC4442987, DOI: 10.4088/jcp.13m08934.Peer-Reviewed Original ResearchConceptsHeavy drinking daysBlood alcohol concentrationPercent days abstinentDrinking daysNumber of drinksYoung adultsDays abstinentPercent heavy drinking daysOutpatient research centerSafety of naltrexonePlacebo-controlled studySerious adverse eventsRisk-benefit ratioPercentage of daysAdverse eventsSecondary outcomesPrimary outcomeFrequency of drinkingOpioid antagonistAdult heavy drinkersAlcohol drinkingClinical trialsEvaluable samplesYoung adult heavy drinkersTreatment period
2014
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias AJ, Gelernter J, Gueorguieva R, Ralevski E, Petrakis IL. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2014, 23: 288-293. PMID: 24724887, PMCID: PMC4600600, DOI: 10.1111/j.1521-0391.2014.12102.x.Peer-Reviewed Original ResearchMeSH KeywordsAlcohol DeterrentsAlcoholismDiagnosis, Dual (Psychiatry)DisulfiramDopamine beta-HydroxylaseDrug Therapy, CombinationFemaleGenotypeHeterozygoteHumansMaleMental DisordersMiddle AgedNaltrexoneNarcotic AntagonistsPolymorphism, Single NucleotideReceptors, Opioid, muTreatment OutcomeVeteransWhite PeopleConceptsAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsOPRM1 rs1799971Favorable responseMore abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinking
2013
Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans
Arias A, Gelernter J, Gueorguieva R, Ralevski E, Petrakis I. Pharmacogenetics of naltrexone and disulfiram in alcohol dependent, dually diagnosed veterans. American Journal On Addictions 2013 DOI: 10.1111/j.1521-0391.2013.12102.x.Peer-Reviewed Original ResearchAllele carriersHeavy drinkingCo-occurring alcohol dependenceT allele carriersAlcohol-dependent subjectsAD treatment responseTreatment of individualsPrimary outcomePharmacogenetic interactionsHigher overall rateTreatment responseAxis INaltrexoneT carriersEuropean-American subjectsFavorable responseOPRM1 rs1799971More abstinenceAlcohol dependenceDependent subjectsDBH rs1611115DisulfiramGenotyped subjectsAbstinenceLess drinking
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply